Brand Name Drug Companies Barrel Ahead with Business-As-Usual Approach to Price-Gouging Patients
For Immediate ReleaseContact: Jon Conradi860-235-3884[email protected]
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Tuesday reacting to a new round of price hikes from Big Pharma to start the month of July, as part of traditional biannual increases from the pharmaceutical industry. According to data from Analysource, so far this month, “59 manufacturers raise[d] prices on 105 brands.”
“Big Pharma continues to barrel ahead with a business-as-usual approach to price-gouging American patients while pointing fingers for out-of-control drug prices at everyone else in the supply chain,” said CSRxP executive director Lauren Aronson. “Big Pharma’s egregious July price hikes highlight that drug companies alone set, and increase, prices on their products and underscore why Congress must focus on holding Big Pharma accountable to effectively lower prescription drug prices for patients.”
Big Pharma has a long history of hiking prices, oftentimes at rates above inflation, escalating the crisis of affordability for Americans who face financial uncertainty purchasing their medications and imposing heavy costs on taxpayers.
Biannual Price Hikes
Examples of Big Pharma price hikes so far this year include:
Read more about Big Pharma’s July price hikes HERE.
Read more about Big Pharma’s price increases in January of this year HERE.
Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.